Product Images Gemcitabine

This is a product identification label that contains a GTIN (Global Trade Item Number), SN (Serial Number), expiration date (in year-month format), and LOT (a unique code that identifies a specific batch of the product). The actual values for each of these fields are not provided in the text.*

This appears to be a statistical analysis of the median progression-free survival rates of two different chemotherapy treatments, Gemcitabine/Carboplatin and Carboplatin, with N=178 individuals in each group. The Gemcitabine/Carboplatin treatment had a median PFS of 8.6 months, while the Carboplatin treatment had a median PFS of 5.8 months. The results indicate that the Gemcitabine/Carboplatin treatment had a significantly higher PFS rate with a Log rank p-value of 0.0038. The graph shows the PFS rate over time in months for each group.*

This is a description of a clinical trial comparing the efficacy of Gemcitabine/Paclitaxel vs Paclitaxel in the treatment of a disease. The trial shows that Gemcitabine/Paclitaxel had a better median time to documented disease progression (5.2 months) compared to Paclitaxel (2.9 months). This difference was statistically significant with p < 0.0001. The graph shows the progression-free probability over time.*

This is a table presenting data on the probability of survival and median survival time for patients who received Gem/Cis or cisplatin for treatment. The table reports a 39% one-year survival rate for patients who received Gem/Cis with a median survival time of 9.0 months. Meanwhile, patients who received cisplatin saw a one-year survival rate of 28% with a median survival time of 7.6 months. Logrank and Wilcoxon tests were performed, with p-values of 0.008 and 0.018, respectively. The table also includes a column showing the overall survival time in months.*

This is a description of a medication with the name 1DC 0143-9394-01. Exch il cortains gomcitabine HO! equivalent to 200 mg gemetabine, 200 mg mannitol, and 125 mg Gemcitahine. The medication is stored in a cooled room with temperature ranges between 20 - 25 °C. To prepare the injection for intravenous use, one needs to mix the medication with 0.9% of Sodium Chloride Injection that contains no preservatives. The medication comes in single-dose vial packaging, and any unused portion should be discarded.*

This is a description of a medication called Gemcitabine for Injection, USP which comes in a sterile single-dose vial. The medication is used intravenously and is stored at controlled temperatures between 20 to 25°C. To reconstitute the medication, 5ml of 0% Sodium Chloride is added to make a solution. Any unused portion should be discarded.*

Gemcitabine for Injection is a medication that is available in 1 gram vials for intravenous use only. It contains gemcitabine HC, mannitol, and sodium acetate. The pH is adjusted with hydrochloric acid and/or sodium hydroxide. The solution should be stored at room temperature and should be administered within 24 hours after reconstitution. The medication should not be refrigerated, and any unused portion should be discarded. The manufacturer is THYMOORGAN PHARMAZE G from Germany. Lot number 127.206.025/01.*

Gemcitabine for Injection, USP is a drug wrapped in a sterile 1-gram vial. It is made by THVMGORGAN PHARMAZIE. The drug is ought for intravenous use only. Any unused portion of the drug must be discarded. It is distributed and labeled by Hikma Pharmaceuticals and is not available over the counter.*